Overview
ARGX market data
Price History
ARGX price chart
Valuation & Profitability
- P/E (TTM)
- 22.19 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $19.57 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.29 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 47.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $556.80 – $833.60 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $47.6B · P/B 6.92 · P/S 10.51.
Company News
argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.Globenewswire Inc · Aug 6, 2026, 12:15 PM
argenx Commences $77/Shr Cash Tender Offer Through Subsidiary Avena Merger Sub To Acquire All Outstanding Shares Of Forte BiosciencesBenzinga · Aug 6, 2026, 11:59 AM
Guggenheim Reinstates Buy on argenx, Maintains $1185 Price TargetBenzinga · Aug 5, 2026, 1:42 PM
Wedbush Maintains Outperform on argenx, Raises Price Target to $1050Benzinga · Jul 28, 2026, 12:54 PM
Crude Oil Falls Sharply; US Durable Goods Orders Increase 0.3% In JuneBenzinga · Jul 27, 2026, 4:22 PM
Argenx Secures Promising Autoimmune Drug In Forte Biosciences TakeoverBenzinga · Jul 27, 2026, 4:16 PM
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks Moving Higher On MondayBenzinga · Jul 27, 2026, 2:35 PM
Baird Maintains Neutral on argenx, Raises Price Target to $932Benzinga · Jul 27, 2026, 11:58 AM
Why Forte Biosciences Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving PremarketBenzinga · Jul 27, 2026, 9:09 AM
Argenx To Acquire Forte Biosciences For $77 Per Share Cash, Valuing Deal At ~$2.2B, Adding CD122-Targeting FB102 With Vitiligo And Celiac DataBenzinga · Jul 27, 2026, 5:23 AM